Objective To investigate the effect of patient-controlled subcutaneous analgesia （PCSA） with sufentanil on analgesia and quality of life in patients with cancer pain at home. Methods A total of 85 patients with cancer pain who were admitted from March 2023 to March 2025 were selected and divided into a control group and an observation group according to the random number table method, with 45 cases in each group. Five cases dropped off in the observation group, and 40 cases were finally included in the observation group. Patients in the control group were treated with oral morphine for analgesia, and patients in the observation group were treated with sufentanil PCSA. The quality of life [Karnofsky performance scale （KPS）] and pain [numerical rating scale （NRS）] before and after treatment and the incidence of adverse reactions during treatment were compared between the two groups. Results After treatment, the NRS scores in both groups were lower than those before treatment （P<0.05）. The NRS score of the control group was higher than that of the observation group, and the KPS score was lower of the control group than that of the observation group （P<0.05）. The pain relief rate of the control group was 71.11%, which was lower than 95.00% of the observation group （P<0.05）. The incidence of adverse reactions after treatment in the observation group was 30.00%, which was significantly lower than 53.33% in the control group （P<0.05）. Conclusion Sufentanil PCSA has a good analgesic effect on patients with cancer pain at home, can improve the quality of life of patients, and has high safety.
WU Haibin
,
ZHAO Chunjiang
,
HE Chenghui
,
ZHANG Guoqiang
,
OU Jianying
. Effect of sufentanil patient-controlled subcutaneous analgesia on analgesia and quality of life in patients with cancer pain at home[J]. Surgical Research and New Technique, 2025
, 14(4)
: 343
-347
.
DOI: 10.3969/j.issn.2095-378X.2025.04.009
[1] Raad M, Lopez WOC, Sharafshan A, et al.Personalized medicine in cancer pain management[J]. J Pers Med,2023,13(8):1201.
[2] 安颂歌,王馨曼,魏方,等. 抑癌止痛散联合曲马多缓释片对原发性肝癌癌性疼痛疗效、肝癌标志物及T细胞亚群的影响[J].中西医结合肝病杂志,2024,34(1):2320-2327.
[3] Ganguly A, Michael M, Goschin S, et al.Cancer pain and opioid use disorder. Oncology (Williston Park).2022,36(9):535-541.
[4] 张立勇,张艳,罗孔亮. 复方苦参注射液联合舒芬太尼对晚期癌症患者镇痛疗效、抗肿瘤因子水平及不良反应发生率的影响[J]. 现代医学,2020,48(10):1315-1318.
[5] Zeng X, Zhu J, Li J, et al.Patient controlled subcutaneous analgesia of hydromorphone versus morphine to treat moderate and severe cancer pain: a randomized double-blind controlled trial[J]. J Pain Symptom Manage,2024,67(1):50-58.
[6] 托利森,萨特思韦特,宋文阁,等. 临床疼痛学[M]. 济南:山东科学技术出版社,2004:600-601.
[7] 李春蕊,张雯,樊碧发. 数字评分法(NRS)与口述评分法(VRS)在老年慢性疼痛患者中的比较[J]. 中国疼痛医学杂志,2016,22(9):683-686.
[8] Schag CC, Heinrich RL, Ganz PA.Karnofsky performance status revisited:reliability,validity,and guidelines[J]. J Clin Oncol,1984,2(3):187-193.
[9] 石远凯,孙燕. 临床肿瘤内科手册[M]. 5版. 北京:人民卫生出版社,2014.
[10] Brozovic G, Lesar N, Janev D, et al.Cancer pain and therapy[J]. Acta Clin Croat,2022,61(Suppl 2):103-108.
[11] Xiao F, Du B, Zhang H, et al.Clinical efficacy of sufentanil combined with dexmedetomidine in patient-controlled subcutaneous analgesia for advanced cancer pain[J]. Pak J Pharm Sci,2023,36(3 Special):947-951.
[12] Coates S, Lazarus P.Hydrocodone, oxycodone, and morphine metabolism and drug-drug interactions[J]. J Pharmacol Exp Ther, 2023,387(2):150-169.
[13] 冯婷,张静月,孙东光,等. 普瑞巴林联合盐酸吗啡缓释片治疗前列腺癌神经病理性癌痛的临床疗效研究[J]. 标记免疫分析与临床,2023,30(5):753-757.
[14] 孟明华,邹长玲,吕慎娟,等. 舒芬太尼静脉自控镇痛对宫颈癌术后患者疼痛及应激反应的影响[J]. 分子诊断与治疗杂志,2023,15(7):1225-1228.
[15] 刘玉婷,文进秋,侯彦深,等. 右美托咪定复合舒芬太尼病人自控静脉镇痛对胸腔镜下肺癌根治术病人术后免疫功能及呼吸功能恢复的影响[J]. 临床外科杂志,2024,32(7):767-771.
[16] Liu D, Li W, Chen L.Comparison of the efficacy of sufentanil and morphine titration for patient-controlled subcutaneous analgesia in severe advanced cancer pain[J]. Pak J Med Sci, 2023,39(2):561-566.
[17] 严志勇,汪涛,吴浩,等. BMI对行胸腔镜下肺癌根治术老年病人术后舒芬太尼个体化镇痛效果的影响[J]. 实用老年医学,2023,37(7):676-679.
[18] 肖芳芳,杜宝昌,毕利萍,等. 舒芬太尼皮下自控镇痛治疗晚期癌痛的临床观察[J]. 中国疼痛医学杂志,2022,28(1):73-75.
[19] 彭娜,柯世莉,李貌,等. 肺癌晚期患者癌性疼痛管理障碍的影响因素及护理对策[J]. 护理实践与研究,2020,17(12):38-40.
